news flash·2025-05-21 07:47Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its heavy tartrate norepinephrine injection (specification: 1ml:2mg), successfully passing the consistency evaluation for generic drugs [1] Group 1: Product Approval and Market Impact - The heavy tartrate norepinephrine injection is primarily used for blood pressure control in certain acute hypotensive states, as well as for assisting treatment in cardiac arrest and severe hypotension [1] - The company submitted the consistency evaluation supplementary application for the 1ml:2mg specification to the National Medical Products Administration in June 2024, which has been accepted [1] - As of the announcement date, the company has invested approximately RMB 1.6 million in R&D expenses for the consistency evaluation of this product [1] Group 2: Market Potential - The total procurement amount for heavy tartrate norepinephrine injection (1ml:2mg) in hospitals across mainland China in 2024 is RMB 1.584 billion [1] - Drugs that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions, which is beneficial for expanding the market share of this product and enhancing its market competitiveness [1]